Related Experiment Video
Updated: Jul 28, 2026
08:38
Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Tacrolimus and myocardial hypertrophy
Y Nakata1, M Yoshibayashi, T Yonemura
1Department of Pediatrics, Kyoto University Faculty of Medicine, Kurashiki Central Hospital, Okayama, Japan.
Transplantation
|June 1, 2000
Summary
Tacrolimus can cause heart muscle thickening (hypertrophic cardiomyopathy) in transplant patients. This condition is linked to blood levels of tacrolimus and is reversible, with no significant symptoms observed.
Area of Science:
- Cardiology
- Pharmacology
- Transplantation Medicine
Background:
- Tacrolimus is a vital immunosuppressant for solid organ transplantation.
- Tacrolimus-induced hypertrophic cardiomyopathy is an uncommon but serious complication.
- Understanding the tacrolimus-cardiac hypertrophy relationship is crucial for patient management.
Purpose of the Study:
- To investigate the correlation between tacrolimus blood levels and myocardial hypertrophy.
- To assess the reversibility of tacrolimus-induced cardiac wall thickening.
- To determine the clinical significance of tacrolimus-associated myocardial hypertrophy.
Main Methods:
- Prospective study monitoring tacrolimus blood levels in transplant recipients.
- Echocardiographic assessment of cardiac wall thickness.
- Correlation analysis between tacrolimus concentrations and left ventricular hypertrophy.
Main Results:
- Tacrolimus-induced myocardial hypertrophy showed a positive correlation with tacrolimus blood levels.
- Cardiac hypertrophy induced by tacrolimus was found to be reversible upon monitoring.
- No patients in the study group developed clinically significant symptoms related to the observed myocardial hypertrophy.
Conclusions:
- Tacrolimus blood levels are directly associated with the development of myocardial hypertrophy.
- Tacrolimus-induced cardiac changes are reversible, suggesting potential for therapeutic adjustments.
- Close monitoring of tacrolimus levels and cardiac function is essential in transplant patients to mitigate risks.
More Related Videos
08:00Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity
Published on: July 10, 2019
07:02Operating Transverse Aortic Constriction with Absorbable Suture to Obtain Transient Myocardial Hypertrophy
Published on: September 9, 2020
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:21Myocarditis I: Introduction
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...